Company intelligence
Nicox
Maintain vision and improve ocular health
Pharmaceutical Manufacturing
Valbonne, FR
44 employees
Founded 1996
3 public signals
About Nicox
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com
Verified activity
Signals from Nicox
3 published signals
Capital & Finance
Nicox announced an extension of its financial horizon allowing existing operations to be funded beyond the first quarter of 2028.
Reported by Nicox
Capital & Finance
Nicox announced an extension of its cash runway with existing operations funded beyond Q1 2028, pushing the NCX 470 U.S. NDA approval milestone into 2029.
Reported by Nicox
Strategy & Corporate Development
Nicox has financed its current operational structure into early 2028 and potentially into and beyond 2029 to provide a stable foundation for future development.
Reported by Gavin Spencer